Henry Schein Gets a Hold Rating from Barclays


Barclays analyst Steven Valiquette maintained a Hold rating on Henry Schein (NASDAQ: HSIC) yesterday and set a price target of $73. The company’s shares closed yesterday at $71.08.

According to TipRanks.com, Valiquette is a 4-star analyst with an average return of 8.3% and a 54.0% success rate. Valiquette covers the Services sector, focusing on stocks such as AmerisourceBergen Corporation, Walgreens Boots Alliance, and Patterson Companies Inc.

Currently, the analyst consensus on Henry Schein is Moderate Buy and the average price target is $79.25, representing an 11.5% upside.

In a report issued on April 24, Goldman Sachs also downgraded the stock to Hold with a $72 price target.

See today’s analyst top recommended stocks >>

Henry Schein’s market cap is currently $10.92B and has a P/E ratio of 26.68. The company has a Price to Book ratio of 3.89.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts